575 related articles for article (PubMed ID: 16175516)
1. Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery.
Agnelli G; Bergqvist D; Cohen AT; Gallus AS; Gent M;
Br J Surg; 2005 Oct; 92(10):1212-20. PubMed ID: 16175516
[TBL] [Abstract][Full Text] [Related]
2. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicenter, randomized, placebo-controlled, double-blind study.
Eriksson BI; Lassen MR;
Arch Intern Med; 2003 Jun; 163(11):1337-42. PubMed ID: 12796070
[TBL] [Abstract][Full Text] [Related]
3. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery.
Bauer KA; Eriksson BI; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1305-10. PubMed ID: 11794149
[TBL] [Abstract][Full Text] [Related]
4. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery.
Eriksson BI; Bauer KA; Lassen MR; Turpie AG;
N Engl J Med; 2001 Nov; 345(18):1298-304. PubMed ID: 11794148
[TBL] [Abstract][Full Text] [Related]
5. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients.
Leizorovicz A; Cohen AT; Turpie AG; Olsson CG; Vaitkus PT; Goldhaber SZ;
Circulation; 2004 Aug; 110(7):874-9. PubMed ID: 15289368
[TBL] [Abstract][Full Text] [Related]
6. Fondaparinux for prevention of venous thromboembolism in major orthopedic surgery.
Tran AH; Lee G
Ann Pharmacother; 2003 Nov; 37(11):1632-43. PubMed ID: 14565815
[TBL] [Abstract][Full Text] [Related]
7. A meta-analysis of fondaparinux versus enoxaparin in the prevention of venous thromboembolism after major orthopaedic surgery.
Turpie AG; Eriksson BI; Lassen MR; Bauer KA
J South Orthop Assoc; 2002; 11(4):182-8. PubMed ID: 12597061
[TBL] [Abstract][Full Text] [Related]
8. The safety and efficacy of extended thromboprophylaxis with fondaparinux after major orthopedic surgery of the lower limb with or without a neuraxial or deep peripheral nerve catheter: the EXPERT Study.
Singelyn FJ; Verheyen CC; Piovella F; Van Aken HK; Rosencher N;
Anesth Analg; 2007 Dec; 105(6):1540-7, table of contents. PubMed ID: 18042845
[TBL] [Abstract][Full Text] [Related]
9. Venous thromboembolism prophylaxis: role of factor xa inhibition by fondaparinux.
Turpie AG
Surg Technol Int; 2004; 13():261-7. PubMed ID: 15744699
[TBL] [Abstract][Full Text] [Related]
10. Prevention of major venous thromboembolism following total hip or knee replacement: a randomized comparison of low-molecular-weight heparin with unfractionated heparin (ECHOS Trial).
Haas S; Breyer HG; Bacher HP; Fareed J; Misselwitz F; Victor N; Weber J;
Int Angiol; 2006 Dec; 25(4):335-42. PubMed ID: 17164738
[TBL] [Abstract][Full Text] [Related]
11. Fondaparinux: an update on new study results.
Bauersachs RM
Eur J Clin Invest; 2005 Mar; 35 Suppl 1():27-32. PubMed ID: 15701145
[TBL] [Abstract][Full Text] [Related]
12. A comparative double-blind, randomised trial of a new second generation LMWH (bemiparin) and UFH in the prevention of post-operative venous thromboembolism. The Bemiparin Assessment group.
Kakkar VV; Howes J; Sharma V; Kadziola Z
Thromb Haemost; 2000 Apr; 83(4):523-9. PubMed ID: 10780310
[TBL] [Abstract][Full Text] [Related]
13. A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Eriksson BI; Arfwidsson AC; Frison L; Eriksson UG; Bylock A; Kälebo P; Fager G; Gustafsson D
Thromb Haemost; 2002 Feb; 87(2):231-7. PubMed ID: 11858482
[TBL] [Abstract][Full Text] [Related]
14. Dermatan sulphate for the prevention of postoperative venous thromboembolism in patients with cancer. DOS (Dermatan sulphate in Oncologic Surgery) Study Group.
Di Carlo V; Agnelli G; Prandoni P; Coccheri S; Gensini GF; Gianese F; Mannucci PM
Thromb Haemost; 1999 Jul; 82(1):30-4. PubMed ID: 10456450
[TBL] [Abstract][Full Text] [Related]
15. The safety of fondaparinux for the prevention and treatment of venous thromboembolism.
Turpie AG
Expert Opin Drug Saf; 2005 Jul; 4(4):707-21. PubMed ID: 16011449
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial.
Cohen AT; Davidson BL; Gallus AS; Lassen MR; Prins MH; Tomkowski W; Turpie AG; Egberts JF; Lensing AW;
BMJ; 2006 Feb; 332(7537):325-9. PubMed ID: 16439370
[TBL] [Abstract][Full Text] [Related]
17. Low molecular weight heparin for the prevention of venous thromboembolism after abdominal surgery.
Bergqvist D
Br J Surg; 2004 Aug; 91(8):965-74. PubMed ID: 15286956
[TBL] [Abstract][Full Text] [Related]
18. A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement.
Turpie AG; Gallus AS; Hoek JA;
N Engl J Med; 2001 Mar; 344(9):619-25. PubMed ID: 11228275
[TBL] [Abstract][Full Text] [Related]
19. Fondaparinux for prevention of venous thromboembolism in high-risk trauma patients: a pilot study.
Lu JP; Knudson MM; Bir N; Kallet R; Atkinson K
J Am Coll Surg; 2009 Nov; 209(5):589-94. PubMed ID: 19854398
[TBL] [Abstract][Full Text] [Related]
20. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
